REFERENCES
1. Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
2. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-57.
6. Jamalinia M, Lonardo A, Weiskirchen R. Sex and gender differences in liver fibrosis: pathomechanisms and clinical outcomes. Fibrosis. 2024;2:10006.
7. Joo SK, Kim W. Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review. Ewha Med J. 2024;47:e17.
8. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:61-71.e15.
10. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708.
11. Moghaddasifar I, Lankarani KB, Moosazadeh M, et al. Prevalence of non-alcoholic fatty liver disease and its related factors in iran. Int J Organ Transplant Med. 2016;7:149-60.
12. Burra P, Bizzaro D, Gonta A, et al.; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713-33.
13. Alkaabi J, Afandi B, Alhaj O, Kanwal D, Agha A. Identifying metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus using clinic-based prediction tools. Front Med. 2024;11:1425145.
14. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
15. Hayward KL, Johnson AL, Horsfall LU, Moser C, Valery PC, Powell EE. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol. 2021;8:e000572.
16. Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity. World J Hepatol. 2021;13:1584-610.
17. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43:508-14.
18. Eguchi Y, Hyogo H, Ono M, et al.; JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-95.
19. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237-43.
20. Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406-14.
21. Shen M, Shi H. Sex hormones and their receptors regulate liver energy homeostasis. Int J Endocrinol. 2015;2015:294278.
22. Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol. 2017;1043:227-56.
23. Galmés-Pascual BM, Martínez-Cignoni MR, Morán-Costoya A, et al. 17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. Free Radic Biol Med. 2020;150:148-60.
24. Galmés-Pascual BM, Nadal-Casellas A, Bauza-Thorbrügge M, et al. 17β-estradiol improves hepatic mitochondrial biogenesis and function through PGC1B. J Endocrinol. 2017;232:297-308.
25. Smiriglia A, Lorito N, Bacci M, et al. Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease. Cell Death Dis. 2025;16:57.
26. Ribas V, Nguyen MT, Henstridge DC, et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. Am J Physiol Endocrinol Metab. 2010;298:E304-19.
27. Zhu L, Brown WC, Cai Q, et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes. 2013;62:424-34.
28. Matsuo K, Gualtieri MR, Cahoon SS, et al. Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer. Menopause. 2016;23:189-96.
29. Mueller NT, Liu T, Mitchel EB, et al. Sex hormone relations to histologic severity of pediatric nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2020;105:3496-504.
30. Pafili K, Paschou SA, Armeni E, Polyzos SA, Goulis DG, Lambrinoudaki I. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. J Endocrinol Invest. 2022;45:1609-23.
31. Ryu S, Suh BS, Chang Y, et al. Menopausal stages and non-alcoholic fatty liver disease in middle-aged women. Eur J Obstet Gynecol Reprod Biol. 2015;190:65-70.
32. Meda C, Dolce A, Della Torre S. Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues. Clin Mol Hepatol. 2025;31:327-32.
33. Markopoulos MC, Kassi E, Alexandraki KI, Mastorakos G, Kaltsas G. Hyperandrogenism after menopause. Eur J Endocrinol. 2015;172:R79-91.
34. Zaman A, Rothman MS. Postmenopausal hyperandrogenism: evaluation and treatment strategies. Endocrinol Metab Clin North Am. 2021;50:97-111.
35. Gershagen S, Doeberl A, Jeppsson S, Rannevik G. Decreasing serum levels of sex hormone-binding globulin around the menopause and temporary relation to changing levels of ovarian steroids, as demonstrated in a longitudinal study. Fertil Steril. 1989;51:616-21.
36. Lazo M, Zeb I, Nasir K, et al. Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol. 2015;13:1686-93.e2.
37. Polyzos SA, Kountouras J, Tsatsoulis A, et al. Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones. 2013;12:405-16.
38. Larsson H, Ahrén B. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women. Diabetes Care. 1996;19:1399-403.
39. Wang N, Zhai H, Zhu C, et al. Combined association of vitamin D and sex hormone binding globulin with nonalcoholic fatty liver disease in men and postmenopausal women: a cross-sectional study. Medicine. 2016;95:e2621.
40. Flechtner-Mors M, Schick A, Oeztuerk S, et al.; EMIL-Study Group. Associations of fatty liver disease and other factors affecting serum SHBG concentrations: a population based study on 1657 subjects. Horm Metab Res. 2014;46:287-93.
41. Wang X, Xie J, Pang J, et al. Serum SHBG is associated with the development and regression of nonalcoholic fatty liver disease: a prospective study. J Clin Endocrinol Metab. 2020;105:e791-804.
42. Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol. 2017;16:382-94.
43. Mahmoud M, Kawtharany H, Awali M, Mahmoud N, Mohamed I, Syn WK. The effects of testosterone replacement therapy in adult men with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2025;16:e00787.
44. Lee HS, Han SH, Swerdloff R, Pak Y, Budoff M, Wang C. The effect of testosterone replacement therapy on nonalcoholic fatty liver disease in older hypogonadal men. J Clin Endocrinol Metab. 2024;109:e757-64.
45. Kumarendran B, O’Reilly MW, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. PLoS Med. 2018;15:e1002542.
46. Park JM, Lee HS, Oh J, Lee YJ. Serum testosterone level within normal range is positively associated with nonalcoholic fatty liver disease in premenopausal but not postmenopausal women. J Womens Health. 2019;28:1077-82.
47. Sarkar MA, Suzuki A, Abdelmalek MF, et al.; NASH Clinical Research Network. Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD. Clin Gastroenterol Hepatol. 2021;19:1267-74.e1.
48. Sayas-Barberá E, Pérez-Álvarez JA, Navarro-Rodríguez de Vera C, Fernández-López M, Viuda-Martos M, Fernández-López J. Sustainability and gender perspective in food innovation: foods and food processing coproducts as source of macro- and micro-nutrients for woman-fortified foods. Foods. 2022;11:3661.
49. Nasreddine L, Chamieh MC, Ayoub J, Hwalla N, Sibai AM, Naja F. Sex disparities in dietary intake across the lifespan: the case of Lebanon. Nutr J. 2020;19:24.
50. Feraco A, Armani A, Amoah I, et al. Assessing gender differences in food preferences and physical activity: a population-based survey. Front Nutr. 2024;11:1348456.
51. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34:309-38.
52. Loeffelholz C, Coldewey SM, Birkenfeld AL. A narrative review on the role of AMPK on de novo lipogenesis in non-alcoholic fatty liver disease: evidence from human studies. Cells. 2021;10:1822.
53. Morán-Costoya A, Proenza AM, Gianotti M, Lladó I, Valle A. Sex differences in nonalcoholic fatty liver disease: estrogen influence on the liver-adipose tissue crosstalk. Antioxid Redox Signal. 2021;35:753-74.
54. Goul C, Peruzzo R, Zoncu R. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat Rev Mol Cell Biol. 2023;24:857-75.
55. Basil B, Myke-Mbata BK, Eze OE, Akubue AU. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol. 2024;10:39.
56. Nemer M, Osman F, Said A. Dietary macro and micronutrients associated with MASLD: analysis of a national US cohort database. Ann Hepatol. 2024;29:101491.
57. Tramunt B, Smati S, Grandgeorge N, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63:453-61.
58. Low WS, Cornfield T, Charlton CA, Tomlinson JW, Hodson L. Sex differences in hepatic de novo lipogenesis with acute fructose feeding. Nutrients. 2018;10:1263.
59. Piras IS, Raju A, Don J, Schork NJ, Gerhard GS, DiStefano JK. Hepatic PEMT expression decreases with increasing NAFLD severity. Int J Mol Sci. 2022;23:9296.
60. Wang C, Ma H, Yang H, et al. Sex differences in the association between total energy intake and all-cause mortality among patients with metabolic dysfunction-associated steatotic liver disease. Sci Rep. 2025;15:19176.
61. O’Meara L, de Bruyn J, Hope T, et al. Conceptual framework of women’s food environments and determinants of food acquisition and dietary intake in low- and middle-income countries: a scoping review. Lancet Planet Health. 2025;9:101280.
62. Sinclair K, Thompson-colón T, Bastidas-granja AM, Del Castillo Matamoros SE, Olaya E, Melgar-quiñonez H. Women’s autonomy and food security: connecting the dots from the perspective of indigenous women in rural Colombia. SSM Qual Res Health. 2022;2:100078.
63. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;17:374-444.
64. Chen Y, Kim M, Paye S, Benayoun BA. Sex as a biological variable in nutrition research: from human studies to animal models. Annu Rev Nutr. 2022;42:227-50.
65. Trouwborst I, Goossens GH, Astrup A, Saris WHM, Blaak EE. Sexual dimorphism in body weight loss, improvements in cardiometabolic risk factors and maintenance of beneficial effects 6 months after a low-calorie diet: results from the randomized controlled DiOGenes trial. Nutrients. 2021;13:1588.
66. Bédard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex-related differences in the effects of the mediterranean diet on glucose and insulin homeostasis. J Nutr Metab. 2014;2014:424130.
67. Leblanc V, Bégin C, Hudon AM, et al. Gender differences in the long-term effects of a nutritional intervention program promoting the Mediterranean diet: changes in dietary intakes, eating behaviors, anthropometric and metabolic variables. Nutr J. 2014;13:107.
68. D’Abbondanza M, Ministrini S, Pucci G, et al. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: the role of sex differences. Nutrients. 2020;12:2748.
69. Vitale M, Costabile G, Bergia RE, et al. The effects of Mediterranean diets with low or high glycemic index on plasma glucose and insulin profiles are different in adult men and women: data from MEDGI-Carb randomized clinical trial. Clin Nutr. 2023;42:2022-8.
70. Razzak I, Fares A, Stine JG, Trivedi HD. The role of exercise in steatotic liver diseases: an updated perspective. Liver Int. 2025;45:e16220.
71. Kretschmer L, Salali GD, Andersen LB, et al.; International Children’s Accelerometry Database (ICAD) Collaborators. Gender differences in the distribution of children’s physical activity: evidence from nine countries. Int J Behav Nutr Phys Act. 2023;20:103.
72. Hurley KS, Flippin KJ, Blom LC, Bolin JE, Hoover DL, Judge LW. Practices, perceived benefits, and barriers to resistance training among women enrolled in college. Int J Exerc Sci. 2018;11:226-38.
73. Reading JM, LaRose JG. Exercise preferences among emerging adults: do men and women want different things? J Am Coll Health. 2022;70:1301-5.
74. Pataky MW, Dasari S, Michie KL, et al. Impact of biological sex and sex hormones on molecular signatures of skeletal muscle at rest and in response to distinct exercise training modes. Cell Metab. 2023;35:1996-2010.e6.
75. Freer CL, George ES, Tan SY, Abbott G, Dunstan DW, Daly RM. Effect of progressive resistance training with weight loss compared with weight loss alone on the fatty liver index in older adults with type 2 diabetes: secondary analysis of a 12-month randomized controlled trial. BMJ Open Diabetes Res Care. 2022;10:e002950.
76. Keating SE, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science Australia. Sports Med. 2023;53:2347-71.
77. Kling K, Margaryan L, Fuchs M. (In) equality in the outdoors: gender perspective on recreation and tourism media in the Swedish mountains. Current Issues in Tourism. 2020;23:233-47.
78. Merino M, Tornero-Aguilera JF, Rubio-Zarapuz A, Villanueva-Tobaldo CV, Martín-Rodríguez A, Clemente-Suárez VJ. Body perceptions and psychological well-being: a review of the impact of social media and physical measurements on self-esteem and mental health with a focus on body image satisfaction and its relationship with cultural and gender factors. Healthcare. 2024;12:1396.
79. Nournezhad H, Davar S, Vahabzadeh D, Mohaddesi H, Sahebazzamani Z, Yas A. Physical activity and food frequency in postmenopausal women: a cross-sectional study. J Midwifery Reprod Health. 2023;11:3734-43.
80. Zhang Z, He Z, Yang H, Li D, Duan P, Wei X. The accumulation of visceral fat in postmenopausal women: the combined impact of prenatal genetics, epigenetics, and fat depot heterogeneity - a descriptive review. Clin Exp Obstet Gynecol. 2025;52:26194.
81. Curci R, Bonfiglio C, Franco I, Bagnato CB, Verrelli N, Bianco A. Leisure-time physical activity in subjects with metabolic-dysfunction-associated steatotic liver disease: an all-cause mortality study. J Clin Med. 2024;13:3772.
82. Mosca L, Mochari H, Christian A, et al. National study of women’s awareness, preventive action, and barriers to cardiovascular health. Circulation. 2006;113:525-34.
83. Williams RL, Wood LG, Collins CE, Callister R. Effectiveness of weight loss interventions--is there a difference between men and women: a systematic review. Obes Rev. 2015;16:171-86.
84. Rinaldi R, De Nucci S, Donghia R, et al. Gender differences in liver steatosis and fibrosis in overweight and obese patients with metabolic dysfunction-associated steatotic liver disease before and after 8 weeks of very low-calorie ketogenic diet. Nutrients. 2024;16:1408.
85. Gratacós-Ginès J, Ariño S, Sancho-Bru P, Bataller R, Pose E. MetALD: clinical aspects, pathophysiology and treatment. JHEP Rep. 2025;7:101250.
86. Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65:102292.
87. Israelsen M, Torp N, Johansen S, et al.; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218-28.
88. Dunn N, Al-Khouri N, Abdellatif I, Singal AK. Metabolic dysfunction and alcohol-associated liver disease: a narrative review. Clin Transl Gastroenterol. 2025;16:e00828.
89. Bizzaro D, Becchetti C, Trapani S, et al.; AISF Special Interest Group on Gender in Hepatology. Influence of sex in alcohol-related liver disease: pre-clinical and clinical settings. United European Gastroenterol J. 2023;11:218-27.
90. White AM. Gender differences in the epidemiology of alcohol use and related harms in the United States. Alcohol Res. 2020;40:01.
91. Xu J, Li Y, Feng Z, Chen H. Cigarette smoke contributes to the progression of MASLD: from the molecular mechanisms to therapy. Cells. 2025;14:221.
92. Kopp W. Pathogenesis of (smoking-related) non-communicable diseases-evidence for a common underlying pathophysiological pattern. Front Physiol. 2022;13:1037750.
93. Alcaraz A, Lazo E, Casarini A, et al. Exploring gender disparities in the disease and economic tobacco-attributable burden in Latin America. Front Public Health. 2023;11:1321319.
94. Kim NH, Jung YS, Hong HP, et al. Association between cotinine-verified smoking status and risk of nonalcoholic fatty liver disease. Liver Int. 2018;38:1487-94.
96. Yoo JJ, Lee DH, Kim SG, Jang JY, Kim YS, Kim LY. Impacts of smoking on alcoholic liver disease: a nationwide cohort study. Front Public Health. 2024;12:1427131.
97. Aryee LNA, Flanagan SV, Trupe L, Yucel M, Smith J. Social norms and social opportunities: a qualitative study of influences on tobacco use among urban adolescent girls in Ghana. BMC Public Health. 2024;24:2978.
98. Gezinski LB, Gonzalez-Pons KM, Rogers MM. Substance use as a coping mechanism for survivors of intimate partner violence: implications for safety and service accessibility. Violence Against Women. 2021;27:108-23.
99. Fonseca F, Robles-Martínez M, Tirado-Muñoz J, et al. A gender perspective of addictive disorders. Curr Addict Rep. 2021;8:89-99.
100. Rata Mohan DS, Jawahir S, Manual A, et al. Gender differences in health-seeking behaviour: insights from the National Health and Morbidity Survey 2019. BMC Health Serv Res. 2025;25:900.
101. Schlichthorst M, Sanci LA, Pirkis J, Spittal MJ, Hocking JS. Why do men go to the doctor? BMC Public Health. 2016;16:1028.
102. Mokhwelepa LW, Sumbane GO. Men’s mental health matters: the impact of traditional masculinity norms on men’s willingness to seek mental health support; a systematic review of literature. Am J Mens Health. 2025;19:15579883251321670.
103. Straw I, Wu H. Investigating for bias in healthcare algorithms: a sex-stratified analysis of supervised machine learning models in liver disease prediction. BMJ Health Care Inform. 2022;29:e100457.
104. Stefanova V, Farrell L, Latu I. Gender and the pandemic: associations between caregiving, working from home, personal and career outcomes for women and men. Curr Psychol. 2023;42:17395-411.
105. Sarkar M, Kushner T. Metabolic dysfunction-associated steatotic liver disease and pregnancy. J Clin Invest. 2025;135:e186426.
106. Sarkar M, Grab J, Dodge JL, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol. 2020;73:516-22.
107. Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2016;4:1025-36.
108. Kushner T, Lange M, Argiriadi PA, Meislin R, Sigel K, Terrault N; Fatty Liver In Pregnancy (FLIP) Study Group. Prevalence, risk profiles, and national implications of nonalcoholic fatty liver disease in pregnant individuals. Clin Gastroenterol Hepatol. 2024;22:194-6.e1.
109. Lee SM, Kwak SH, Koo JN, et al. Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. Diabetologia. 2019;62:238-48.
110. Lee SM, Kim BJ, Koo JN, et al. Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight. PLoS One. 2019;14:e0221400.
111. Armistead B, Johnson E, VanderKamp R, et al. Placental regulation of energy homeostasis during human pregnancy. Endocrinology. 2020;161:bqaa076.
112. Hagström H, Höijer J, Ludvigsson JF, et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int. 2016;36:268-74.
113. De Souza LR, Berger H, Retnakaran R, et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol. 2016;111:665-70.
114. Mousa N, Abdel-Razik A, Shams M, et al. Impact of non-alcoholic fatty liver disease on pregnancy. Br J Biomed Sci. 2018;75:197-9.
115. Herath RP, Siriwardana SR, Ekanayake CD, Abeysekara V, Kodithuwakku SUA, Herath HP. Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: a cross sectional analytical study. PLoS One. 2019;14:e0215326.
116. Sattari M, Bril F, Egerman R, Kalavalapalli S, Cusi K. Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. J Investig Med. 2020;68:743-7.
117. Lee SM, Jung YM, Choi ES, et al. Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes. Clin Gastroenterol Hepatol. 2022;20:2542-50.e8.
118. Qian Y, Zhang Y, Fan X, et al. Nonalcoholic fatty liver disease and adverse pregnancy outcomes in women with normal prepregnant weight. J Clin Endocrinol Metab. 2023;108:463-71.
119. Jafari R, Karimi Moghaddam E, Ahmadzadeh A, Bahrami S, Alavinejad P, Manouchehri Zanjani S. Pregnancy outcome in patients with non-alcoholic fatty liver disease: a prospective cohort study. Gastroenterol Hepatol Bed Bench. 2024;17:180-6.
120. Koralegedara IS, Warnasekara JN, Dayaratne KG, De Silva FN, Premadasa JK, Agampodi SB. Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages-prospective study in Rajarata Pregnancy Cohort (RaPCo). BMJ Open Gastroenterol. 2022;9:e000831.
121. Amadou C, Nabi O, Serfaty L, et al. Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort. Hepatology. 2022;76:1438-51.
122. Jamaly H, Eslick GD, Weltman M. Systematic review with meta-analysis: non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol. 2022;28:52-66.
123. Lee SM, Hwangbo S, Norwitz ER, et al. Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods. Clin Mol Hepatol. 2022;28:105-16.
124. Sosseh SAL, Barrow A, Lu ZJ. Cultural beliefs, attitudes and perceptions of lactating mothers on exclusive breastfeeding in The Gambia: an ethnographic study. BMC Womens Health. 2023;23:18.
125. Cohen CC, Perng W, Sauder KA, et al. Maternal diet quality during pregnancy and offspring hepatic fat in early childhood: the healthy start study. J Nutr. 2023;153:1122-32.
126. Sarkar M, Brady CW, Fleckenstein J, et al. Reproductive health and liver disease: practice guidance by the american association for the study of liver diseases. Hepatology. 2021;73:318-65.
127. Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J Hepatol. 2023;79:768-828.
128. Spatz DL, Rodríguez SÁ, Benjilany S, et al. Having enough milk to sustain a lactation journey: a call to action. Nurs Womens Health. 2024;28:256-63.
129. Ayonrinde OT, Oddy WH, Adams LA, et al. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. J Hepatol. 2017;67:568-76.
130. Soullane S, Willems P, Lee GE, Auger N. Early life programming of nonalcoholic fatty liver disease in children. Early Hum Dev. 2022;168:105578.
131. Leca BM, Lagojda L, Kite C, et al. Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review. Expert Rev Endocrinol Metab. 2024;19:335-48.
132. Hagström H, Simon TG, Roelstraete B, Stephansson O, Söderling J, Ludvigsson JF. Maternal obesity increases the risk and severity of NAFLD in offspring. J Hepatol. 2021;75:1042-8.
133. Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology. 2020;158:1967-83.e1.
134. Zeng J, Shen F, Zou ZY, et al. Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring. World J Gastroenterol. 2022;28:1681-91.
135. Şanlı E, Kabaran S. Maternal obesity, maternal overnutrition and fetal programming: effects of epigenetic mechanisms on the development of metabolic disorders. Curr Genomics. 2019;20:419-27.
136. Forbes JD, Azad MB, Vehling L, et al.; Canadian Healthy Infant Longitudinal Development (CHILD) Study Investigators. Association of exposure to formula in the hospital and subsequent infant feeding practices with gut microbiota and risk of overweight in the first year of life. JAMA Pediatr. 2018;172:e181161.
137. Wesolowski SR, Kasmi KC, Jonscher KR, Friedman JE. Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol. 2017;14:81-96.
138. Park Y, Sinn DH, Oh JH, et al. The association between breastfeeding and nonalcoholic fatty liver disease in parous women: a nation-wide cohort study. Hepatology. 2021;74:2988-97.
139. Ajmera VH, Terrault NA, Van Wagner LB, et al. Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. J Hepatol. 2019;70:126-32.
140. Marshall NE, Lau B, Purnell JQ, Thornburg KL. Impact of maternal obesity and breastfeeding intention on lactation intensity and duration. Matern Child Nutr. 2019;15:e12732.
141. Bish MR, Faulks F, Amir LH, et al. Relationship between obesity and lower rates of breast feeding initiation in regional Victoria, Australia: an 8-year retrospective panel study. BMJ Open. 2021;11:e044884.
142. Karachaliou GS, Suzuki A, Patel VA, Bastian LA, Diehl AM, Abdelmalek MF; Duke NAFLD Clinical Research Working Group. Longer breastfeeding duration is associated with decreased risk of hepatic fibrosis among young women with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2024;22:413-5.e3.
143. Lund-Blix NA, Dydensborg Sander S, Størdal K, et al. Infant feeding and risk of type 1 diabetes in two large scandinavian birth cohorts. Diabetes Care. 2017;40:920-7.
144. Abeysekera KW, Orr JG, Madley-Dowd P, et al. Association of maternal pre-pregnancy BMI and breastfeeding with NAFLD in young adults: a parental negative control study. Lancet Reg Health Eur. 2021;10:100206.
145. Yamakawa M, Yorifuji T, Inoue S, Kato T, Doi H. Breastfeeding and obesity among schoolchildren: a nationwide longitudinal survey in Japan. JAMA Pediatr. 2013;167:919-25.
146. Tørris C, Bjørnnes AK. Duration of lactation and maternal risk of metabolic syndrome: a systematic review and meta-analysis. Nutrients. 2020;12:2718.
147. Kardashian A, Kushner T, Au JS, et al.; AASLD Women’s Initiative Committee. The key role of hepatology providers in optimizing reproductive care in patients with liver disease: a call to action. Hepatology. 2023;78:363-7.
148. Glintborg D, Møller JK, Rubin KH, et al. Gender-affirming treatment and mental health diagnoses in Danish transgender persons: a nationwide register-based cohort study. Eur J Endocrinol. 2023;189:336-45.
149. Hilden M, Glintborg D, Andersen MS, et al. Gender incongruence in Denmark, a quantitative assessment. Acta Obstet Gynecol Scand. 2021;100:1800-5.
150. Harper J, O’Donnell E, Sorouri Khorashad B, McDermott H, Witcomb GL. How does hormone transition in transgender women change body composition, muscle strength and haemoglobin? Br J Sports Med. 2021;55:865-72.
151. Spanos C, Bretherton I, Zajac JD, Cheung AS. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: a systematic review. World J Diabetes. 2020;11:66-77.
152. Velho I, Fighera TM, Ziegelmann PK, Spritzer PM. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology. 2017;5:881-8.
153. Klaver M, van Velzen D, de Blok C, et al. Change in visceral fat and total body fat and the effect on cardiometabolic risk factors during transgender hormone therapy. J Clin Endocrinol Metab. 2022;107:e153-64.
154. Shadid S, Abosi-Appeadu K, De Maertelaere AS, et al. Effects of gender-affirming hormone therapy on insulin sensitivity and incretin responses in transgender people. Diabetes Care. 2020;43:411-7.
155. Islam N, Nash R, Zhang Q, et al. Is there a link between hormone use and diabetes incidence in transgender people? J Clin Endocrinol Metab. 2022;107:e1549-57.
156. van Velzen D, Wiepjes C, Nota N, et al. Incident diabetes risk is not increased in transgender individuals using hormone therapy. J Clin Endocrinol Metab. 2022;107:e2000-7.
157. Hashemi L, Marijic Buljubasic A, Budoff MJ, et al. Gender-affirming hormone treatment and metabolic syndrome among transgender veterans. JAMA Netw Open. 2024;7:e2419696.
158. Pei Q, Song Y, Huang Z, et al. Effects of gender-affirming hormone therapy on body fat: a retrospective case-control study in Chinese transwomen. Lipids Health Dis. 2024;23:146.
159. Schutte MH, Kleemann R, Nota NM, et al. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS One. 2022;17:e0261312.
160. Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D, Irwig MS. Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension. 2021;77:2066-74.
161. Lake JE, Hyatt AN, Feng H, et al. Transgender women with HIV demonstrate unique non-alcoholic fatty liver disease profiles. Transgend Health. 2024;9:413-20.
162. Lightner JS, Schneider J, Grimes A, et al. Physical activity among transgender individuals: a systematic review of quantitative and qualitative studies. PLoS One. 2024;19:e0297571.
163. Jones BA, Haycraft E, Bouman WP, Arcelus J. The levels and predictors of physical activity engagement within the treatment-seeking transgender population: a matched control study. J Phys Act Health. 2018;15:99-107.
164. Goffnett J, Call J, Ciak J, et al. Conceptualizing trans-inclusive healthcare in the United States: environmental and interpersonal factors of healthcare provision. SSM - Health Systems. 2025;5:100112.
165. Waters J, Linsenmeyer W. The impact of gender-affirming hormone therapy on nutrition-relevant biochemical measures. Front Nutr. 2024;11:1339311.
166. Cherubini A, Della Torre S, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol Med. 2024;30:1126-36.
167. Kim H, Kim SE, Sung MK. Sex and gender differences in obesity: biological, sociocultural, and clinical perspectives. World J Mens Health. 2025;43:758-72.
168. Lee JH, Jeon S, Lee HS, Kwon YJ. Gender differences in the risk for incident non-alcoholic fatty liver disease according to the transition of abdominal obesity status: a 16-year cohort study. Nutrients. 2023;15:2880.
169. Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78:1048-62.
170. Bansal S, Vachher M, Arora T, Kumar B, Burman A. Visceral fat: a key mediator of NAFLD development and progression. Hum Nutr Metab. 2023;33:200210.
171. Gavin KM, Bessesen DH. Sex differences in adipose tissue function. Endocrinol Metab Clin North Am. 2020;49:215-28.
172. Kuryłowicz A. Estrogens in adipose tissue physiology and obesity-related dysfunction. Biomedicines. 2023;11:690.
173. Holven KB, Roeters van Lennep J. Sex differences in lipids: a life course approach. Atherosclerosis. 2023;384:117270.
174. Tsutsumi T, Kawaguchi T, Fujii H, et al. Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025;60:891-904.
175. Sun T, Liu J. Study on the correlation between triglyceride glucose index, triglyceride glucose index to high-density lipoprotein cholesterol ratio, and the risk of diabetes in nonalcoholic fatty liver disease. Front Endocrinol. 2025;16:1594548.
176. Chen H, Miao X, Hu M, et al. Associations between high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and their ratio with metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study. Front Endocrinol. 2025;16:1585811.
177. Oortmerssen JAE, Mulder JWCM, Kavousi M, Roeters van Lennep JE. Lipid metabolism in women: a review. Atherosclerosis. 2025;405:119213.
178. Milani I, Chinucci M, Leonetti F, Capoccia D. MASLD: prevalence, mechanisms, and sex-based therapies in postmenopausal women. Biomedicines. 2025;13:855.
179. Ntikoudi A, Spyrou A, Evangelou E, Dokoutsidou E, Mastorakos G. The effect of menopausal status, insulin resistance and body mass index on the prevalence of non-alcoholic fatty liver disease. Healthcare. 2024;12:1081.
180. Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol. 2023;79:1524-41.
181. Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66:986-1002.
182. Huang C, Yang X, Liu J. Sex-based differences in the predictive significance of the waist circumference glucose index for future diabetes risk. Sci Rep. 2025;15:21477.
183. Manjarrés L, Xavier A, González L, et al. Sex differences in the relationship between body composition and MASLD progression in a murine model of metabolic syndrome. iScience. 2025;28:111863.
184. Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36:947-68.
185. Tao Z, Cheng Z. Hormonal regulation of metabolism-recent lessons learned from insulin and estrogen. Clin Sci. 2023;137:415-34.
186. Paoli M, Zakharia A, Werstuck GH. The role of estrogen in insulin resistance: a review of clinical and preclinical data. Am J Pathol. 2021;191:1490-8.
187. Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22:1999-2010.e8.
188. de Abreu JDMF, Azulay RS, Rodrigues V, et al. Predictors of hepatic fibrosis in type 2 diabetes patients with metabolic-dysfunction-associated steatotic liver disease. Biomedicines. 2024;12:2542.
189. Melini S, Trinchese G, Lama A, et al. Sex differences in hepatic inflammation, lipid metabolism, and mitochondrial function following early lipopolysaccharide exposure in epileptic WAG/Rij rats. Antioxidants. 2024;13:957.
190. Chadalavada S, Jensen MT, Aung N, et al. Women with diabetes are at increased relative risk of heart failure compared to men: insights from UK biobank. Front Cardiovasc Med. 2021;8:658726.
191. Zhang F, Han Y, Zheng G, Li W. Gender differences in the incidence of nephropathy and changes in renal function in patients with type 2 diabetes mellitus: a retrospective cohort study. Diabetes Metab Syndr Obes. 2024;17:943-57.
192. Gowda D, Shekhar C, B
193. Arvanitakis K, Chatzikalil E, Kalopitas G, et al. Metabolic dysfunction-associated steatotic liver disease and polycystic ovary syndrome: a complex interplay. J Clin Med. 2024;13:4243.
194. Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med. 2025;12:1539283.
195. Nakagami H. Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension. Hypertens Res. 2023;46:539-41.
196. Yeo WJ, Abraham R, Surapaneni AL, et al. Sex differences in hypertension and its management throughout life. Hypertension. 2024;81:2263-74.
197. Chapman N, Ching SM, Konradi AO, et al. Arterial hypertension in women: state of the art and knowledge gaps. Hypertension. 2023;80:1140-9.
198. Burnside J, Cinque F, Sebastiani G, et al. Sex differences in the prevalence and cardiometabolic risk profiles of steatotic liver disease: a Canadian longitudinal study on aging analysis. Can J Public Health. 2025:Epub ahead of print.
199. Orhan İ, Koçak HS, Kaplan E. Determination of cardiometabolic risk in pre- and post-menopausal women. BMC Cardiovasc Disord. 2025;25:399.
200. Bager JE, Manhem K, Andersson T, et al. Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care. J Hum Hypertens. 2023;37:662-70.
201. Eng PC, Forlano R, Tan T, Manousou P, Dhillo WS, Izzi-Engbeaya C. Non-alcoholic fatty liver disease in women - current knowledge and emerging concepts. JHEP Rep. 2023;5:100835.
202. Chen M, Cao Y, Ji G, Zhang L. Lean nonalcoholic fatty liver disease and sarcopenia. Front Endocrinol. 2023;14:1217249.
203. Sookoian S, Rotman Y, Valenti L. Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update. Clin Gastroenterol Hepatol. 2024;22:2177-87.e3.
204. Link JC, Wiese CB, Chen X, et al. X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity. J Clin Invest. 2020;130:5688-702.
205. Chen X, McClusky R, Chen J, et al. The number of x chromosomes causes sex differences in adiposity in mice. PLoS Genet. 2012;8:e1002709.
206. Reue K. Sex differences in obesity: X chromosome dosage as a risk factor for increased food intake, adiposity and co-morbidities. Physiol Behav. 2017;176:174-82.
207. Mondal S, Gargari P, Bose C, Garg MK, Chowdhury S, Mukhopadhyay S. Abnormal body composition increases the cardiometabolic risk in adolescents and young adults with turner syndrome. Endocr Pract. 2024;30:259-69.
208. Singh I, Noel G, Barker JM, et al. Hepatic abnormalities in youth with Turner syndrome. Liver Int. 2022;42:2237-46.
209. Twohig P, Li L, Danford D, Craft M, Yetman AT. Prevalence of hepatic steatosis and fibrosis in Turner syndrome: a prospective case-control study. Liver Int. 2024;44:1309-15.
210. Viuff MH, Stochholm K, Grønbaek H, Berglund A, Juul S, Gravholt CH. Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome - a nationwide cohort study. Aliment Pharmacol Ther. 2021;53:821-9.
211. Zaegel N, Brahimaj R, Battaglia-Hsu S, Lamiral Z, Feigerlova E. Systemic inflammatory indices and liver dysfunction in turner syndrome patients: a retrospective case-control study. J Endocr Soc. 2024;8:bvae099.
212. Link JC, Chen X, Arnold AP, Reue K. Metabolic impact of sex chromosomes. Adipocyte. 2013;2:74-9.
213. Link JC, Reue K. Genetic basis for sex differences in obesity and lipid metabolism. Annu Rev Nutr. 2017;37:225-45.
214. Calcaterra V, Brambilla P, Maffè GC, et al. Metabolic syndrome in Turner syndrome and relation between body composition and clinical, genetic, and ultrasonographic characteristics. Metab Syndr Relat Disord. 2014;12:159-64.
215. Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29:1591-8.
216. Høst C, Skakkebæk A, Groth KA, Bojesen A. The role of hypogonadism in Klinefelter syndrome. Asian J Androl. 2014;16:185-91.
217. Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol. 2004;151:657-87.
218. Bardsley MZ, Falkner B, Kowal K, Ross JL. Insulin resistance and metabolic syndrome in prepubertal boys with Klinefelter syndrome. Acta Paediatr. 2011;100:866-70.
219. Nagral A, Bangar M, Menezes S, et al. Gender differences in nonalcoholic fatty liver disease. Euroasian J Hepatogastroenterol. 2022;12:S19-25.
220. Fiot E, Zénaty D, Boizeau P, Haignere J, Dos Santos S, Léger J; French Turner Syndrome Study Group. X chromosome gene dosage as a determinant of congenital malformations and of age-related comorbidity risk in patients with Turner syndrome, from childhood to early adulthood. Eur J Endocrinol. 2019;180:397-406.
221. Bourcigaux N, Dubost E, Buzzi JC, et al. Focus on liver function abnormalities in patients with turner syndrome: risk factors and evaluation of fibrosis risk. J Clin Endocrinol Metab. 2023;108:2255-61.
222. Ridder LOR, Just J, Hvas CL, et al. Elevated liver enzymes in turner syndrome: the role of low-grade inflammation and hormonal imbalances. J Endocr Soc. 2025;9:bvaf059.
223. Wójcik M, Ruszała A, Januś D, Starzyk JB. Liver biochemical abnormalities in adolescent patients with turner syndrome. J Clin Res Pediatr Endocrinol. 2019;11:395-9.
224. El-Mansoury M, Berntorp K, Bryman I, et al. Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. Clin Endocrinol. 2008;68:485-90.
225. Marrone A, Allosso F, Caturano A, et al. Metabolic dysfunction-associated steatotic liver disease in klinefelter syndrome: high prevalence uncovers an unmet need. J Clin Endocrinol Metab. 2025:Epub ahead of print.
226. Davis SM, Nokoff NJ, Furniss A, et al. Population-based assessment of cardiometabolic-related diagnoses in youth with klinefelter syndrome: a PEDSnet study. J Clin Endocrinol Metab. 2022;107:e1850-9.
227. Cherubini A, Ostadreza M, Jamialahmadi O, et al.; EPIDEMIC Study Investigators. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med. 2023;29:2643-55.
228. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883-94.
229. Rosso C, Caviglia GP, Birolo G, et al. Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21:3314-21.e3.
230. Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. The protection conferred by HSD17B13 rs72613567 polymorphism on risk of steatohepatitis and fibrosis may be limited to selected subgroups of patients with NAFLD. Clin Transl Gastroenterol. 2021;12:e00400.
231. Smyk W, Papapostoli I, Żorniak M, et al. Liver phenotypes in PCOS: analysis of exogenous and inherited risk factors for liver injury in two European cohorts. Liver Int. 2023;43:1080-8.
232. Pirola CJ, Salatino A, Quintanilla MF, Castaño GO, Garaycoechea M, Sookoian S. The influence of host genetics on liver microbiome composition in patients with NAFLD. EBioMedicine. 2022;76:103858.
233. Wang J, Zhu N, Su X, Gao Y, Yang R. Gut-microbiota-derived metabolites maintain gut and systemic immune homeostasis. Cells. 2023;12:793.
234. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369-79.
235. Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol. 2019;17:296-306.
236. Liu HX, Keane R, Sheng L, Wan YJ. Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol. 2015;63:1502-10.
237. Zheng Z, Wang B. The gut-liver axis in health and disease: the role of gut microbiota-derived signals in liver injury and regeneration. Front Immunol. 2021;12:775526.
238. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-75.
239. de la Cuesta-Zuluaga J, Kelley ST, Chen Y, et al. Age- and sex-dependent patterns of gut microbial diversity in human adults. mSystems. 2019;4:e00261-19.
240. Dominianni C, Sinha R, Goedert JJ, et al. Sex, body mass index, and dietary fiber intake influence the human gut microbiome. PLoS One. 2015;10:e0124599.
241. Mayneris-Perxachs J, Arnoriaga-Rodríguez M, Luque-Córdoba D, et al. Gut microbiota steroid sexual dimorphism and its impact on gonadal steroids: influences of obesity and menopausal status. Microbiome. 2020;8:136.
242. Santos-Marcos JA, Mora-Ortiz M, Tena-Sempere M, Lopez-Miranda J, Camargo A. Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases. Biol Sex Differ. 2023;14:4.
243. Sheng L, Jena PK, Liu HX, et al. Gender differences in bile acids and microbiota in relationship with gender dissimilarity in steatosis induced by diet and FXR inactivation. Sci Rep. 2017;7:1748.
244. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.
245. Provenzano PF, Caridi G, Parlongo G, et al. Are there sex differences in cardiovascular outcomes in non-dialysis CKD patients? Clin Kidney J. 2023;16:2141-6.
246. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457-69.
247. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. focus on clinical aspects and implications for practice and translational research. J Clin Med. 2020;9:1278.
248. Pemmasani G, Yandrapalli S, Aronow W. Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. Am J Cardiovasc Dis. 2020;10:362-6.
249. Khalid YS, Dasu NR, Suga H, et al. Increased cardiovascular events and mortality in females with NAFLD: a meta-analysis. Am J Cardiovasc Dis. 2020;10:258-71.
250. Jamalinia M, Zare F, Mantovani A, Targher G, Lonardo A. Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: a meta-analysis. Diabetes Obes Metab. 2025;27:5171-81.
251. García GG, Iyengar A, Kaze F, Kierans C, Padilla-Altamira C, Luyckx VA. Sex and gender differences in chronic kidney disease and access to care around the globe. Semin Nephrol. 2022;42:101-13.
252. Yan T, Zhang X, Wong T, Cheung R, Nguyen MH. Sex differences in adverse liver and nonliver outcomes in steatotic liver disease. JAMA Netw Open. 2024;7:e2448946.
253. Sinn DH, Kang D, Jang HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol. 2017;67:1274-80.
254. Park H, Dawwas GK, Liu X, Nguyen MH. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med. 2019;286:711-22.
255. Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J. 2020;8:942-8.
256. Ho JK, Thurairajah PH, Leo J, Huang DQ, Fan KH. Sex differences in hepatocellular carcinoma. Hepatoma Res. 2024;10:53.
257. Nevola R, Tortorella G, Rosato V, et al. Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma. Biology. 2023;12:984.
258. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148:72-83.
259. Wu EM, Wong LL, Hernandez BY, et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 2018;4:66.
260. Zhang X, Nguyen MH. Metabolic dysfunction-associated steatotic liver disease: a sexually dimorphic disease and breast and gynecological cancer. Metabolism. 2025;167:156190.
261. Shi Y, Zhang X, Wong T, et al. Sex differences in risk of adverse liver events in patients with cirrhosis. JAMA Netw Open. 2025;8:e2523674.
262. Peng Y, Wang P, Liu F, et al. Metabolic dysfunction-associated steatotic liver disease and cancer risk: a cohort study. Diabetes Obes Metab. 2025;27:1940-9.
263. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71:778-88.
264. Vali Y, van Dijk AM, Lee J, et al.; LITMUS investigators. Precision in liver diagnosis: varied accuracy across subgroups and the need for variable thresholds in diagnosis of MASLD. Liver Int. 2025;45:e16240.
265. Calès P, Canivet CM, Costentin C, et al. A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD. J Hepatol. 2025;82:794-804.
266. Ji H, Cheng S; Heart-Liver Axis Research Collaboration. Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: biological sex matters. J Hepatol. 2024;80:e68-9.
267. Ramírez-Vélez R, Izquierdo M, García-Hermoso A, Correa-Rodríguez M. Reference values and associated factors of controlled attenuation parameter and liver stiffness in adults: a cross-sectional study. Nutr Metab Cardiovasc Dis. 2024;34:1879-89.
268. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
269. Yadav AK, MacNeill JJ, Krylov A, et al. Sex- and age-associated factors drive the pathophysiology of MASLD. Hepatol Commun. 2024;8:e0523.
270. Priego-parra BA, Triana-romero A, Martínez-pérez GP, et al. Hepatic steatosis index (HSI): a valuable biomarker in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD). Annals of Hepatology. 2024;29:101391.
271. Xu B, Li C, Chen M, Zhang Y. Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease. Explor Endocr Metab Dis. 2024;1:62-76.
272. Crudele L, De Matteis C, Novielli F, et al. Fatty liver index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men. Biol Sex Differ. 2024;15:43.
273. Westerbacka J, Cornér A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360-9.
274. North KE, Graff M, Franceschini N, et al. Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European American and African American participants of the NHLBI family heart study. Eur J Gastroenterol Hepatol. 2012;24:9-16.
275. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449-57.
276. Trembling PM, Apostolidou S, Gentry-Maharaj A, et al. The enhanced liver fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. BMC Gastroenterol. 2020;20:104.
277. Liguori A, Esposto G, Ainora ME, et al. Liver elastography for liver fibrosis stratification: a comparison of three techniques in a biopsy-controlled MASLD cohort. Biomedicines. 2025;13:138.
278. Cai X, Thorand B, Hohenester S, et al. Association of sex hormones and sex hormone-binding globulin with liver fat in men and women: an observational and Mendelian randomization study. Front Endocrinol. 2023;14:1223162.
279. Gong J, Chen A, Han Y, Xie L. Sex- and age-specific differences in the relationship between fatty liver index as well as fibrosis-4 score and arterial stiffness: results from fuzhou study. J Hypertens. 2025;43:e241.
280. Feng Q, Izzi-Engbeaya CN, Manousou P, Woodward M. Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK biobank. BMC Gastroenterol. 2025;25:546.
281. Gbadamosi SO, Nagelhout E, Sienko D, et al. Association of index and changes in fibrosis-4 score with outcomes in metabolic dysfunction-associated steatohepatitis. Gastro Hep Adv. 2025;4:100666.
282. Park H, Yoon EL, Ito T, et al. Diagnostic performance of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in lean adults with nonalcoholic fatty liver disease. JAMA Netw Open. 2023;6:e2329568.
283. Hinkson A, Lally H, Gibson H, et al. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther. 2023;57:750-62.
284. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486-501.
285. Drygalski K. Pharmacological treatment of MASLD: contemporary treatment and future perspectives. Int J Mol Sci. 2025;26:6518.
286. Hider AM, Bonham A, Carlin A, et al. Association of sex differences on weight loss and complications following bariatric surgery. J Surg Res. 2024;299:359-65.
287. Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393:683-98.
288. Ritter MJ, Amano I, Hollenberg AN. Thyroid hormone signaling and the liver. Hepatology. 2020;72:742-52.
289. Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3, 5-dichloro-4-(5-isopropyl-6-oxo-1, 6-dihydropyridazin-3-yloxy) phenyl]-3, 5-dioxo-2, 3, 4, 5-tetrahydro [1, 2, 4] triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014;57:3912-23.
290. Harrison SA, Bedossa P, Guy CD, et al.; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:1632-3.
291. Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023;79:1557-65.
292. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90.
293. Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20:409-18.
294. Onishi Y, Oura T, Nishiyama H, Ohyama S, Takeuchi M, Iwamoto N. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016;63:263-73.
295. Quan H, Zhang H, Wei W, Fang T. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus. J Diabetes Complications. 2016;30:686-92.
296. Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis. Clin Pharmacokinet. 2016;55:1413-22.
297. Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
298. Yang Y, He L, Han S, et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025;17:e70063.
299. Mirabelli M, Chiefari E, Caroleo P, et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes. Int J Environ Res Public Health. 2019;17:207.
300. Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389:998-1008.
301. Bazhan NМ, Jakovleva TV, Kazantseva AY, et al. Studying sex differences in responses to fibroblast growth factor 21 administration in obese mice consuming a sweet-fat diet. Vavilovskii Zhurnal Genet Selektsii. 2023;27:333-41.
302. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305-15.
303. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279-89.
304. Sanyal AJ, Chalasani N, Kowdley KV, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
305. Yan H, Wu W, Chang X, et al. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ. 2021;12:1.
306. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41:1801-8.
307. Harrison SA, Manghi FP, Smith WB, et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022;28:1432-8.
308. Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735.
309. Sharma A, Wood S, Bell JS, De Blasio MJ, Ilomäki J, Ritchie RH. Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study. Lancet Reg Health West Pac. 2023;33:100692.
310. Liu H, Lefere S, Guillot A, Zheng MH, Tacke F. Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): current knowledge of mechanisms. Hepatology. 2025:Epub ahead of print.
311. McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol. 2006;65:40-4.
312. Florentino GS, Cotrim HP, Vilar CP, Florentino AV, Guimarães GM, Barreto VS. Nonalcoholic fatty liver disease in menopausal women. Arq Gastroenterol. 2013;50:180-5.
313. Kim SE, Min JS, Lee S, Lee DY, Choi D. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration. Sci Rep. 2023;13:15461.
314. Yang JD, Abdelmalek MF, Guy CD, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1479.
315. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
316. Albhaisi S, Kim K, Baker J, et al. LPCN 1144 resolves NAFLD in hypogonadal males. Hepatol Commun. 2020;4:1430-40.
317. Shigehara K, Kato Y, Shinzawa R, et al. Testosterone replacement therapy can improve a biomarker of liver fibrosis in hypogonadal men: a subanalysis of a prospective randomized controlled study in Japan (EARTH Study). World J Mens Health. 2025;43:661-8.
318. Alipour P, Azizi Z, Raparelli V, et al. Role of sex and gender-related variables in development of metabolic syndrome: a prospective cohort study. Eur J Intern Med. 2024;121:63-75.
319. Choudhary NS, Duseja A. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol. 2021;6:2.
320. Lankarani K, Jamalinia M, Zare F, Heydari ST, Ardekani A, Lonardo A. Liver-kidney-metabolic health, sex, and menopause impact total scores and monovessel vs. multivessel coronary artery calcification. Adv Ther. 2025;42:1729-44.
321. Kallen AN, Whirledge S, Goldman KN, Johnson J. Undermining women’s health research - gambling with the public’s health. N Engl J Med. 2025;392:2185-7.
